Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus

Annals of the Rheumatic Diseases

Volumn 67, Issue 8, 2008, Pages 1069-1075

  Nikpour, M ^a   Dempsey, A A ^b   Urowitz, M B ^a,d   Gladman, D D ^a   Barnes, D A ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Xceed Molecular   (Canada)

^c Covance Laboratories ^*  (United States)

^d TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADULT; ARTICLE; BLOOD; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RNA ISOLATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACUTE DISEASE; ADULT; AUTOANTIBODIES; COMPLEMENT SYSTEM PROTEINS; CROSS-SECTIONAL STUDIES; DNA; DNA PROBES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERONS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 47949089923     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.074765     Document Type: Article

References (32)

1. Gladman DD, Urowitz MB. Systemic lupus erythematosus - clinical features. In: Hochberg MC, Silman A, Smolen J, Weinblatt M, Weisman M, eds. Rheumatology. Edinburgh: Mosby, 2003:1359-79.
2. Bombardier C, Gladman DD, Urowitz MB, Carron D, Chang CH, The Committee on Prognosis Studies in SLE. The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992;35:630-40.
3. Gladman DD, Ibañez D, Urowitz MB. SLE Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
4. Fritzler MJ, Elkon KB. Autoantibodies in SLE. In: Hochberg MC, Silman A, Smolen J, Weinblatt M, Weisman M, eds. Rheumatology. Edinburgh: Mosby, 2003:1337-46.
5. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically guiescent SLE. A Discordance between clinical and serological features of SLE. Am J Med 1979;66:210-15.
6. Walz-Leblanc B, Gladman DD, Urowitz MB. Serologically active clinically guiescent SLE, long term follow-up. J Rheumatol 1994;21:174-5
7. Walz-Leblanc B, Gladman DD, Urowitz MB, Goodman PJ. Serologically active clinically quiescent SLE. J Rheumatol 1994;21:2239-41.
8. Gladman DD, Hirani N, Ibañez D, Urowitz MB. Clinically active serologically quiescent (CASD) SLE. J Rheumatol 2003;30:1960-2.
9. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
10. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.
11. Baechler EC, Batiwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-15.
12. Rus V, Atamas SP, Shustova V, Luzina IG, Selaru F, Magder LS, et al. Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol 2002;102:283-90.
13. Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004;138:164-70.
14. Han G-M, Chen S-L, Shen N, Ye S, Bao C-D, Gu Y-Y. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003;4:177-86.
15. Crow MK, Kirou KA. Interferon-α in systemic lupus erythematosus. Curr Opin Rheumatol 2004;16:541-7.
16. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004;16:801-7.
17. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481-90.
18. Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2004;3:505-9.
19. Rus V, Chen H, Zernetkina V, Magder LS, Mathai S, Hochberg MC, et al. Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease. Clin Immunol 2004;112:231-4.
20. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Lee P, Urowitz MB, Bookman AAM, Koehler BE, Smythe HA, Gordon DA, et al. Systemic lupus erythematosus. A review of 110 patients with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977;46:1-32.
23. Gladman DD, Ginzler E, Goldsmith C, Fortin p, Liang M, Urowitz, et al. the development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
24. Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, Liu Y, et al. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int 2007;72:853-64.
25. Ambion. Automated RNA Amplification for Arrays. Ambion Tech Note 2004;11:1.
26. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
27. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004;24:439-54.
28. Doly J, Civas A, Navarro S, Uze G. Type I interferons: expression and signalization. Cell Mol Life Sci 1998;54:1109-21.
29. Ye S, Guo Q, Tang J, Yang C, Shen N, Chen S. Could 2′5′-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot study. Clin Rheumatol 2006;26:186-90.
30. Braun CM, Huang S-K, Bashian GG, Kagey-Sobotka A, Lichtenstein LM, Essayan DM. Corticosteroid modulation of human antigen-specific Th1 and Th2 responses. J Allergy Clin Immunol 1997;100:400-7.
31. Formiga F, Moga I, Pac M, Mitjavila F, Rivera A, Pujol R. Mild presentation of systemic lupus in elderly patients assessed by SLEDAI, SLE Disease Activity Index. Lupus 1999;8:462-5.
32. Tucker LR, Menon S, Schaller JG, Isenberg DA. Adult and childhood onset systemic lupus erythematosus: a comparison of onset, clinical features, serology and outcome. Brit J Rheumatol 1995;34:866-72.